EUS Guided Neurolysis Celiac Block w/wo Bupivacaine in Patient Being Treated Palliatively for Pancreatic Cancer

• Status: Terminated
• Trial end date: 2019-06-14
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this project is to determine if EUS-CPN without Bupivacaine (versus EUS-CPN with Bupivacaine) can reduce pain scores and improve quality of life in patients with inoperable pancreatic cancer by reducing the morbidity due to narcotic side effects (e.g. nausea, excessive sedation, constipation).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• Confirmed malignant pancreatic lesion involving the pancreatic genu, body, or tail

• Abdominal or back pain considered to be potentially related to the tumor

• New onset pain (<3 months)

• Constant

• Centrally located

• With or without irradiation to the back

• No obvious other source of pain based on history and physical examination by the attending endosonographer

• No possibility of surgical management

• Signed, informed consent

Exclusion Criteria:

• Allergy to bupivicaine

• Age < 18 years

• Inability or unwillingness to give informed consent